In the afternoon of May 22, the Nanjing Biomedical Policy Lecture and Enterprise Matchmaking and Exchange Activity jointly sponsored by CPC Nanjing Biomedical Industry Chain Committee, Nanjing Economic and Technological Development Zone CPC Working Committee, and Nanjing Biomedical Industry Attack and Promotion Office was held in Nanjing Astronergy Tianqing Pharmaceutical Co. Ltd. was held. Yin Jun, Deputy Secretary of CPC Working Committee of Nanjing Economic and Technological Development Zone, and Guo Yuming, Director of High and New Technology Department of Municipal Science and Technology Bureau attended the event. More than 60 enterprises from Nanjing Economic Development Zone, Jiangbei New District and Jiangning District attended the activity.
Guo Yuming comprehensively explains the latest biomedical policy of Nanjing, focusing on industrial innovation, achievement transformation, market expansion and other dimensions, from the subsidy policy of "real money" for R&D and innovation, to the ecological construction of industrial parks, to the "green channel" for internationalization and cooperation. "Green Channel", detailed introduction of the policy background, orientation and implementation path. He said that Nanjing biopharmaceutical policy will provide full-cycle support for enterprises, and strive to create a closed loop of services from technology research and development to market application.
Feng Yan, President Assistant of Nanjing Zhengda Tianqing, analyzed the impact of national pharmaceutical policies on the market layout of pharmaceutical enterprises and shared the innovative thinking and execution of head enterprises. Yan Libo, General Manager of Kaiyuan Pharmaceutical, took "Pharmaceuticals and Devices Going Overseas" as the theme and shared the key links in the international certification process and risk prevention and control strategies with practical cases.
Chen Hai, President of Jinling Pharmaceutical, Yin Liu Song, General Manager of Shenghe Bio, Xu Hanmei, Founder of Anji Bio, and many other enterprise leaders exchanged and discussed the topics of "how to cope with the pain points in the development of biopharmaceutical enterprises", "how to strengthen the industry chain synergistic innovation", etc., suggesting that They suggested that we should scientifically balance profits and R&D investment, enhance competitiveness through differentiated innovation, and strengthen the upstream and downstream industry chain "group warming". The insights of the entrepreneurs triggered strong resonance, and the atmosphere of the discussion was warm.
Biomedical industry is one of the strategic emerging industries in Nanjing Economic Development Zone, which has introduced and cultivated nearly 300 biomedical enterprises, including Nanjing Zhengda Tianqing, Novozymes Bio and Haichen Pharmaceuticals, with a leading scale of output value in the city. At present, Nanjing Economic Development Zone is taking "full chain service, full elements of protection" as the core, accelerating the construction of biopharmaceutical industry innovation and development ecology, accelerating the expansion of pharmaceutical enterprises from generic drugs to innovative drugs, and striving to build an industrial cluster covering chemical pharmaceuticals, modern traditional Chinese medicines, biopharmaceuticals and medical devices.
As a next step, Nanjing Economic Development Zone will
Give full play to the biomedical industry chain special class and
The Role of Nanjing Economic Development Zone Chamber of Commerce (Preparation) and Other Platforms
Continuing to deepen the "one-to-one" enterprise service mechanism
Focusing on the needs of enterprises and providing precise counseling
Accelerate policy implementation and strengthen win-win cooperation
Helping enterprises make good use of policy dividends
Jointly promote the development of biomedical industry to a new level
